Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Herbert Patterson

Showing results (31-40 of 69) with videos related to

Pageof 7
Sort By:
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 4, 2013
Relative bioavailability of tolvaptan administered via nasogastric tube and tolvaptan tablets swallowed intactElizabeth B McNeely, Jasmine A Talameh, Kirkwood F Adams, et al.
Journal of Cardiac Failure|February 4, 2010
Health literacy and the patient with heart failure--implications for patient care and research: a consensus statement of the Heart Failure Society of AmericaLorraine S Evangelista, Kismet D Rasmusson, Ann S Laramee, et al.
Clinical Pharmacology and Therapeutics|September 18, 2002
Evaluation of potential losartan-phenytoin drug interactions in healthy volunteersTracy L Fischer, John A Pieper, Donald W Graff, et al.
Journal of Clinical Pharmacology|July 9, 2022
Leveraging a Previously Published Population Pharmacokinetic Model to Predict Rivaroxaban Exposure in Real-World PatientsDaniel Weiner, J Robert Powell, J Herbert Patterson, et al.
European Journal of Heart Failure|February 28, 2014
A perspective on re-evaluating digoxin's role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profileKirkwood F Adams, Jalal K Ghali, J Herbert Patterson, et al.
Pharmacotherapy|November 13, 2004
High-impact articles related to the pharmacotherapeutic management of systolic heart failureTien M H Ng, Orly Carter, Gregory S Guillory, et al.
European Journal of Heart Failure|March 16, 2022
The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from CHAMP-HFAdam D DeVore, Anne S Hellkamp, Laine Thomas, et al.
ESC Heart Failure|November 18, 2021
Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk modelAdam D DeVore, Claude Larry Hill, Laine E Thomas, et al.
Circulation. Heart Failure|June 26, 2020
Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HFAdam D DeVore, Anne S Hellkamp, Laine Thomas, et al.
European Journal of Heart Failure|August 6, 2016
Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trialKirkwood F Adams, Javed Butler, J Herbert Patterson, et al.
Pageof 7

Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 4, 2013
Relative bioavailability of tolvaptan administered via nasogastric tube and tolvaptan tablets swallowed intactElizabeth B McNeely, Jasmine A Talameh, Kirkwood F Adams, et al.
Journal of Cardiac Failure|February 4, 2010
Health literacy and the patient with heart failure--implications for patient care and research: a consensus statement of the Heart Failure Society of AmericaLorraine S Evangelista, Kismet D Rasmusson, Ann S Laramee, et al.
Clinical Pharmacology and Therapeutics|September 18, 2002
Evaluation of potential losartan-phenytoin drug interactions in healthy volunteersTracy L Fischer, John A Pieper, Donald W Graff, et al.
Journal of Clinical Pharmacology|July 9, 2022
Leveraging a Previously Published Population Pharmacokinetic Model to Predict Rivaroxaban Exposure in Real-World PatientsDaniel Weiner, J Robert Powell, J Herbert Patterson, et al.
European Journal of Heart Failure|February 28, 2014
A perspective on re-evaluating digoxin's role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profileKirkwood F Adams, Jalal K Ghali, J Herbert Patterson, et al.
Pharmacotherapy|November 13, 2004
High-impact articles related to the pharmacotherapeutic management of systolic heart failureTien M H Ng, Orly Carter, Gregory S Guillory, et al.
European Journal of Heart Failure|March 16, 2022
The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from CHAMP-HFAdam D DeVore, Anne S Hellkamp, Laine Thomas, et al.
ESC Heart Failure|November 18, 2021
Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk modelAdam D DeVore, Claude Larry Hill, Laine E Thomas, et al.
Circulation. Heart Failure|June 26, 2020
Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HFAdam D DeVore, Anne S Hellkamp, Laine Thomas, et al.
European Journal of Heart Failure|August 6, 2016
Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trialKirkwood F Adams, Javed Butler, J Herbert Patterson, et al.
Pageof 7